Opus Genetics (STU:R3X1) Days Payable : 0.00 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Opus Genetics Days Payable?

Opus Genetics's average Accounts Payable for the three months ended in Dec. 2024 was €1.88 Mil. Opus Genetics's Cost of Goods Sold for the three months ended in Dec. 2024 was €0.00 Mil.

The historical rank and industry rank for Opus Genetics's Days Payable or its related term are showing as below:

STU:R3X1's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 118.34
* Ranked among companies with meaningful Days Payable only.

Opus Genetics's Days Payable stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00). stayed the same

Opus Genetics Days Payable Historical Data

The historical data trend for Opus Genetics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opus Genetics Days Payable Chart

Opus Genetics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Get a 7-Day Free Trial

Opus Genetics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Opus Genetics's Days Payable

For the Biotechnology subindustry, Opus Genetics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opus Genetics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opus Genetics's Days Payable distribution charts can be found below:

* The bar in red indicates where Opus Genetics's Days Payable falls into.

Save Embed

;

Save Embed

;

Opus Genetics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Opus Genetics's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (1.974	+	3.006)	/	2 )	/	0	*	365
=	2.49					/	0	*	365
=	N/A

Opus Genetics's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (0.76	+	3.006)	/	2 )	/	0	*	365 / 4
=	1.883					/	0	*	365 / 4
=	N/A

Opus Genetics Days Payable Related Terms

Thank you for viewing the detailed overview of Opus Genetics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Opus Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opus Genetics Inc (STU:R3X1) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

IRD:USA R3X1:Germany

Address

8 Davis Drive, Suite 220, Durham, NC, USA, 27709

Website

https://www.opusgtx.com

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Opus Genetics Headlines

No Headlines